New immunotherapy target discovered for malignant brain tumors

Scientists say they have discovered a potential new target for immunotherapy of malignant brain tumors, which so far have resisted the ground-breaking cancer treatment based on harnessing the body’s immune system. The discovery, reported in the journal CELL, emerged from laboratory experiments and has no immediate implications for treating patients.

Read more

Key Pathway for Activated T-cells Might Be Targeted to Fight GVHD

The study demonstrates that T cell activation increases intracellular trafficking via the endoplasmic-reticulum-to-Golgi pathway, and that a protein known as SEC23B — a subunit of the COPII complex — regulates T cells’ production of these important secretory proteins after activation. The work points toward a new potential therapeutic target for decreasing the severity of graft-versus-host-disease (GVHD), a potentially fatal complication of bone marrow transplantation.

Read more

Drug-Induced Liver Injury, Translational microRNA Biomarkers, and More Featured in January 2021 Toxicological Sciences

in the January 2021 issue, Toxicological Sciences offers an engaging slate of research in toxicology, from endocrine toxicology and biomarkers to genetic and epigenetic toxicology and mixtures toxicology.

Read more

T Cell Therapy, Gut Microbiome, Tumorigenicity, and More Featured in September 2020 Toxicological Sciences

Toxicological Sciences features leading research in toxicology in the areas of biomarkers, environmental toxicology, and more in the September 2020 issue.

Read more

Deep Look at Immune Cells in Patients’ Tumors Reveals Insights on Timing for Treatment Combinations

It’s clear that radiation therapy, or radiotherapy, an approach used to treat cancer since the early 20th century, can be an effective companion to newer, immune-stimulating approaches known as immunotherapy. Research from a team from Roswell Park Comprehensive Cancer Center explains how radiation helps boost the immune system’s ability to fight cancer in combination with immune checkpoint inhibitors — and provides new evidence that the timing of these therapies can make a big difference in how effectively they work together.

Read more